You are here: Home » Companies » Results
Business Standard

Morepen Q4: Net profit falls 55% to Rs 12 cr, total income up to Rs 371 cr

Drug firm Morepen Laboratories on Thursday said its consolidated net profit declined by 55 per cent to Rs 12 crore for the fourth quarter ended March 2022.

Topics
Morepen Laboratories Ltd | Morepen Laboratories | Q4 Results

Press Trust of India  |  New Delhi 

Indian pharma firms, laboratories

Drug firm on Thursday said its consolidated net profit declined by 55 per cent to Rs 12 crore for the fourth quarter ended March 2022.

The company had reported a net profit of Rs 27 crore in the January-March quarter of 2020-21 fiscal.

Total income increased to Rs 371 crore for the period under review as against Rs 291 crore in the fourth quarter of 2020-21 financial year, said in a regulatory filing.

For the year ended March 31, 2022, the drug firm reported a consolidated net profit of Rs 102 crore as compared to Rs 97 crore in FY 2021.

Total income increased to Rs 1,557 crore during the period under review. It was Rs 1,200 crore in the year-ago period.

"The company has been able to expand its market share and grown in all business segments and expects to increase its profitability parameters in the next few quarters once the supply disruptions are normalised, which have resulted in increased input costs," Chairman and Managing Director Sushil Suri noted.

The company continues to invest in developing new markets and launch new products to reach more and more customers, he added.

He further said: "We have got shareholder's approval for the conversion of bank's preference shares into equity capital, which is underway, while we wait for the regulatory approvals. It will be a big milestone for the company, once the process is completed.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Thu, May 05 2022. 15:55 IST
RECOMMENDED FOR YOU